72
Mostly True
Washington D.C.
The website reports that President Trump signed an order to expedite the review of certain psychedelic drugs, including ibogaine, which remains banned under federal law. The FDA plans to issue priority vouchers for psychedelics, and ibogaine is linked to heart risks and deaths.
The claims regarding President Trump's directive to expedite psychedelic drug reviews, the federal ban on ibogaine, and the legalization of psilocybin therapy in Oregon and Colorado are well-supported by multiple reputable sources. However, the claim about the FDA issuing priority vouchers for psychedelics is contradicted by evidence indicating that psilocybin was removed from such a program. The claim about ibogaine's cardiac risks is also supported by medical literature. Overall, the evidence strongly supports most claims, except for the FDA voucher claim, which lacks support.
Individual Claims
85
True
Politics
President Donald Trump directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.
Multiple reputable sources, including PBS News, Al Jazeera, and NPR, confirm that President Trump signed an order to expedite the review of certain psychedelic drugs, including ibogaine. This aligns with the claim.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
90
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
85
Evidence Summary
3 web sources confirm Trump's order to expedite psychedelic drug reviews.
86
True
Health
Ibogaine and other psychedelics remain banned under the federal government's most restrictive category for illegal, high-risk drugs.
Evidence from multiple sources, including Experience Ibogaine and Americans for Ibogaine, confirms that ibogaine is classified as a Schedule I substance under federal law, indicating it is banned and considered high-risk.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
90
Source Quality Weight
25
Llm Reasoning Score
90
Llm Reasoning Weight
25
Weighted Total
86
Evidence Summary
2 web sources confirm ibogaine's Schedule I status.
29
Mostly False
Health
The FDA will issue national priority vouchers for three psychedelics to allow certain drugs to be approved quickly.
The evidence indicates that psilocybin was removed from the FDA's Priority Voucher program, contradicting the claim that the FDA will issue such vouchers for psychedelics. This suggests the claim is false.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
20
Web Consensus Weight
50
Source Quality Score
20
Source Quality Weight
25
Llm Reasoning Score
30
Llm Reasoning Weight
25
Weighted Total
29
Evidence Summary
1 source contradicts the claim about FDA vouchers for psychedelics.
78
Mostly True
Health
Ibogaine is known to cause irregular heart rhythms and has been linked to more than 30 deaths in the medical literature.
Multiple sources, including Americans for Ibogaine and QxMD, confirm that ibogaine can cause cardiac issues such as QT prolongation and arrhythmias, and has been linked to deaths, supporting the claim.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
78
Evidence Summary
2 sources confirm ibogaine's cardiac risks and associated deaths.
82
True
Politics
Two states, Oregon and Colorado, have legalized psychedelic therapy with psilocybin.
Evidence from multiple sources, including PMC and MycoMeditations, confirms that Oregon and Colorado have legalized psilocybin therapy, supporting the claim.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
90
Llm Reasoning Weight
25
Weighted Total
82
Evidence Summary
2 sources confirm psilocybin legalization in Oregon and Colorado.
